Other Information
−Removed: Rule 10b5-1 Trading Plans – Directors
−Removed: and Section 16 Officers
−Removed: During the three months ended December 31, 2025,
−Removed: none of the Company’s directors or Section 16 officers adopted or terminated any contract, instruction or written plan for the purchase
−Removed: or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or
−Removed: any “non-Rule 10b5-1 trading arrangement”.
+Added: Rule 10b5-1 Trading
+Added: Plans – Directors and Section 16 Officers
+Added: During the three months
+Added: ended March 31, 2026, none of the Company’s directors or Section 16 officers adopted or terminated any contract,
+Added: instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions
+Added: of Rule 10b5-1(c) of the Exchange Act or any “non-Rule 10b5-1 trading arrangement”.
+Added: NeuroOne Medical Technologies Corporation
Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant’s Current Report on Form 8-K filed on June 29, 2017).
Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant’s Current Report on Form 8-K filed on March 31, 2021).
+Added: Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant’s Current Report on Form 8-K filed on April 14, 2026).
Amended and Restated Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant’s Current Report on Form 8-K filed on June 21, 2024).
−Removed: First Amendment to Amended and Restated Exclusive Development and Distribution Agreement with Zimmer, Inc.
−Removed: dated December 31, 2025
+Added: First Amendment to NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 on the Registrant’s Current Report on Form 8-K filed on April 3, 2026).
+Added: Third Amendment to NeuroOne Medical Technologies Corporation 2021 Inducement Plan.
+Added: Third Amendment to Offer Letter between Christopher Volker and the Registrant, dated April 28, 2026.
+Added: Transition and Release Agreement, by and between the Company and Ronald McClurg, dated April 28, 2026 (incorporated by reference to Exhibit 10.1 on the Registrant’s Current Report on Form 8-K filed on April 30, 2026).
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
Filed herewith.
−Removed: Documents are furnished and not filed.
−Removed: NeuroOne Medical Technologies
+Added: Documents are furnished
+Added: and not filed.
+Added: NeuroOne Medical Technologies Corporation
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: February 17, 2026
NeuroOne Medical Technologies Corporation
−Removed: /s/ David Rosa
Chief Executive Officer
(Principal Executive Officer)
−Removed: /s/ Ronald McClurg
Ronald McClurg
Chief Financial Officer
−Removed: (Principal Financial Officer)
+Added: (Principal Financial Officer and Principal Accounting
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.